Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AGIO |
---|---|---|
09:32 ET | 4515 | 48.68 |
09:34 ET | 1592 | 47.9184 |
09:36 ET | 100 | 48.14 |
09:38 ET | 2331 | 48.195 |
09:39 ET | 122 | 48.06 |
09:41 ET | 970 | 48.34 |
09:43 ET | 400 | 48.4 |
09:45 ET | 300 | 48.34 |
09:48 ET | 3673 | 48.245 |
09:50 ET | 927 | 48.27 |
09:52 ET | 900 | 48.405 |
09:54 ET | 700 | 48.25 |
09:56 ET | 300 | 48.24 |
09:57 ET | 1978 | 48.13 |
09:59 ET | 4103 | 47.61 |
10:01 ET | 320 | 47.7 |
10:03 ET | 725 | 47.8 |
10:06 ET | 300 | 47.79 |
10:08 ET | 300 | 47.89 |
10:10 ET | 1324 | 48.08 |
10:12 ET | 300 | 48.155 |
10:15 ET | 100 | 48.215 |
10:17 ET | 817 | 48.135 |
10:19 ET | 5813 | 48.21 |
10:21 ET | 519 | 48.31 |
10:24 ET | 593 | 48.255 |
10:26 ET | 300 | 48.31 |
10:28 ET | 2254 | 48.23 |
10:30 ET | 1700 | 48.255 |
10:32 ET | 1890 | 48.215 |
10:33 ET | 7179 | 48.48 |
10:35 ET | 900 | 48.35 |
10:37 ET | 341 | 48.4 |
10:39 ET | 695 | 48.4 |
10:42 ET | 300 | 48.45 |
10:46 ET | 1475 | 48.46 |
10:48 ET | 1325 | 48.49 |
10:50 ET | 300 | 48.44 |
10:51 ET | 7808 | 48.57 |
10:53 ET | 273 | 48.67 |
10:55 ET | 1600 | 48.62 |
10:57 ET | 300 | 48.5 |
11:00 ET | 300 | 48.495 |
11:02 ET | 1300 | 48.57 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Agios Pharmaceuticals Inc | 2.1B | -7.7x | --- |
Intellia Therapeutics Inc | 2.1B | -4.2x | --- |
Vera Therapeutics Inc | 2.1B | -19.0x | --- |
Recursion Pharmaceuticals Inc | 2.0B | -5.5x | --- |
Geron Corp | 2.1B | -11.3x | --- |
Celldex Therapeutics Inc | 2.2B | -12.1x | --- |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -7.7x |
Price/Sales (TTM) | 70.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.